This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
by Zacks Equity Research
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals
by Zacks Equity Research
RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
by Zacks Equity Research
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
by Zacks Equity Research
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
Roche Antiviral Drug Reduces Transmission in Late-stage Study
by Zacks Equity Research
Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
by Zacks Equity Research
The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.
Tap the Weight-Loss Drug Market With These ETFs
by Sweta Killa
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RHHBY vs. ABBV: Which Stock Is the Better Value Option?
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
by Zacks Equity Research
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
by Zacks Equity Research
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe
by Zacks Equity Research
RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
by Ahan Chakraborty
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug
by Zacks Equity Research
RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
by Zacks Equity Research
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
by Zacks Equity Research
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
The Zacks Analyst Blog Amazon, Roche, GE Aerospace, Canterbury Park and NVE
by Zacks Equity Research
Amazon, Roche, GE Aerospace, Canterbury Park and NVE are included in this Analyst Blog.
Top Analyst Reports for Amazon.com, Roche & GE Aerospace
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Roche Holding AG (RHHBY) and GE Aerospace (GE), as well as two micro-cap stocks Canterbury Park Holding Corporation (CPHC) and NVE Corporation (NVEC).
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
by Zacks Equity Research
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
Affimed Appoints New CEO, Shares Fall on Leadership Change
by Zacks Equity Research
AFMD appoints Shawn M. Leland as the company's new chief executive officer. Stock falls on the news.
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
by Zacks Equity Research
MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
by Zacks Equity Research
Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
by Kinjel Shah
LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
by Zacks Equity Research
RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
Here's Why You Should Consider Buying Akebia (AKBA) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
by Zacks Equity Research
The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.